After a long delay marred by manufacturing troubles, a COVID-19 vaccine from Novavax became the fourth such vaccine authorized in the U.S. We review how it works and how it’s different from its competitors.
In this story, we’ll explain what we know about the financial and conflict-of-interest disclosure requirements for Dr. Anthony Fauci, other National Institutes of Health higher-ups and members of two U.S. vaccine advisory committees.
Children under 5, including those as young as 6 months of age, are now able to be vaccinated against COVID-19. Here, we explain what’s known about the two coronavirus vaccines for the youngest children.
Once scarce, Paxlovid, an antiviral pill that is the preferred treatment for non-hospitalized high-risk COVID-19 patients, is no longer in such short supply. Here, we explain what the drug does, how well it works and what questions remain.
At the end of March, the Food and Drug Administration authorized a second COVID-19 booster dose for people 50 years of age and older. But the data supporting the extra shot is limited. Here, we break down the available evidence and share what scientists recommend.
The demand for at-home, rapid COVID-19 tests — sparked by the fast-spreading omicron variant in December — has continued in 2022. With that demand have come questions about the tests’ efficacy, how to use them and where to get them. We answer those queries and more.
As many Americans and others around the globe prepare for holiday travel and get-togethers, the omicron variant continues to be a concern. While the available data on transmission, vaccine effectiveness and severity of disease are still preliminary, here’s what we’ve learned so far.